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Implantable cardioverter 
defibrillators: Uses, abuses, 
gains and complications
Rapid defibrillation, only when occurring within seconds to minutes 
from the onset of ventricular arrhythmia, can terminate it and 
prevent an otherwise certain death. ICDs however, can detect 
VT and VF and defibrillate rapidly to return the rhythm to normal 
within seconds. Therefore, an ICD implant may conceivably prevent 
SCD and improve long-term survival in patients at risk for life 
threatening ventricular arrhythmias.
However, many issues remain about ICDs and tachycardia 
termination in patients at high risk for SCD. Not all SCD is due to 
VT or VF even if these arrhythmias occur at end of life. In high- 
risk post-myocardial infarction patients, only half of SCDs are due 
to ventricular tachyarrhythmias as determined by recordings using 
an implantable loop recorder.(3)  A haemodynamic death may end 
in fibrillation. Defibrillation will therefore not necessarily make a 
difference. Furthermore, individuals at high risk may have multiple 
co-morbidities that place them at high risk for death irrespective of 
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IntroductIon                                                             
Sudden cardiac death (SCD) is one of the most common causes 
of death.(1) The annual risk of SCD is 0.1-0.2% per year in the 
United States and many other developed countries. Despite 
advances in cardiovascular care, SCD remains a continuing and 
challenging problem. Similarly, in South Africa, challenges remain 
regarding the treatment to reduce the risk of SCD. When a life 
threatening arrhythmia occurs, adequate resuscitation measures 
are rarely available.(2)  
Ventricular tachycardia (VT) or ventricular fibrillation (VF) is a major 
cause of SCD.  Within a few minutes of ventricular fibrillation, poor 
cerebrovascular perfusion leads to incorrectable hypoxic encepha-
lopathy. Resuscitation efforts are generally futile. The short-term 
outcomes of out-of-hospital cardiac arrest were evaluated by 
Stein et al. Five hundred and one adult cardiac arrest cases in 
Johannesburg, South Africa were reviewed.  Of 153 of the 205 
cases with a presumed cardiac cause for cardiac arrest, the median 
response time was 9 minutes and, by that time, only 23% were 
found to have a shockable rhythm. Only 36 of the resuscitated 
cases had return of spontaneous circulation. This was likely due 
to length of response time.(2)  
sudden cardiac death (scd) due to a ventricular arrhyth-
mia is one of the most common causes of death, yet its 
management continues to be a challenge. controlled clinical 
trials have provided evidence that implantable cardioverter 
defibrillators (Icds) are effective in reducing the risk of scd 
in selected patients with ischaemic or non-ischaemic car-
diomyopathy and/or ventricular arrhythmias. As increasing 
numbers of patients become eligible for Icds, deciding 
whom should receive these becomes more complex, es-
pecially in patients with borderline risk factors and those 
with co-morbidities in whom the risk of death from non-
arrhythmic cardiovascular cause is higher. What type of Icd 
a patient should receive remains a challenge. While Icd 
shocks themselves can affect outcomes adversely, no other 
therapy has proven more effective to date. risks of im-
plantation include infection, lead dislodgement and per-
foration. An ongoing challenge which also needs to be 
addressed includes whom will be footing the bill for device 
implants. More data is required to determine which patient 
population will benefit the most from Icd implants.  
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their arrhythmias. Treatment of VT or VF will not necessarily pro-
long long term survival in them. For this reason,  they may not be 
candidates for ICDs based on present data. Not all patients who 
receive ICDs require them. When an ICD is implanted, an inap-
propriate shock for a non-life threatening arrhythmia may result. 
There can be other complications of ICD implants.  
This manuscript will address critical issues regarding ICD use in 
high-risk populations in an attempt to address ICD uses, abuses, 
gains and complications.
Who Is At rIsk for scd?                                          
Determining who is at risk for SCD and likely to benefit from an 
ICD is quite complex. Everyone has some risk for SCD.(4)  Several 
important factors must be considered for an ICD to have a major 
impact in outcomes: 
The risk of SCD due to VT or VF exceeds the risk of mortality 
from other causes;   
The number of patients needed to treat to save one life needs 
to be lower than the potential adverse effects and complications 
from an ICD; and
Costs must be factored into the therapy benefits.  
 
To address some of these issues, the risk of SCD per year and 
the chance of dying from other causes need to be considered. 
Myerberg has considered how the risk of SCD can be transcribed 
into a decision analysis approach:(5) In the overall population, the 
risk of SCD due to VF is very small but the total events per year 
are great due to the size of the population. Alternatively, patients 
who had recent myocardial infarction with severe ventricular 
dysfunction have a high rate of SCD. However, the total number of 
events was small because of the smaller denominator pool in this 
group. Furthermore, these patients may have a high rate of death 
from other causes even if the arrhythmic risk were improved. In the 
middle risk group are patients with heart failure and an impaired 
left ventricular ejection fraction (LVEF). The risk of SCD of this 
patient group is moderate in the range of 10-20% per year.(5) This 
group represents a large population. Therefore, the total events per 
year are modest or large. Not all patients with heart failure and 
impaired LVEF will utilise the ICD. In fact, many of these patients will 
die from non-arrhythmic cardiovascular death or other causes.(6,7) 
Question remains how to predict who benefits most from an ICD. 
■
■
■
All patients with heart disease, such as coronary artery disease, 
valvular heart disease, cardiomyopathy, congestive heart failure and 
non-sustained ventricular tachycardia (NSVT) are at higher risk for 
death than those without heart disease. Even those with normal 
LVEF but diastolic dysfunction may have some risk.(8) Patients who 
have had cardiac arrest and have been resuscitated represent a 
small selected population who are believed to carry an even higher 
risk of SCD. 
WhAt Are the rIsk predIctors?                             
Amongst several predictors of SCD due to VF, two have stood 
the test of time: LVEF and heart failure as determined by functional 
class. These predictors are modulated by other factors, such as, the 
underlying cardiovascular condition; coronary artery disease; valvu-
lar disease; and cardiomyopathy. They are also modulated by co-
morbidities, age and concurrent medications. LVEF is not a linear 
predictor of risk. The risk of SCD increases rapidly when the LVEF 
is <35-40%.(9)  
Various other non-invasive markers have been considered in the 
past. In a study of 416 post-myocardial infarction patients heart 
rate variability, abnormal signal averaged electrocardiography, fre-
quent ventricular ectopy, poor LVEF and impaired Killip class were 
found to predict SCD. Killip class and LVEF were the least pre-
dictive (even though they are often used now). For those patients 
who had a positive heart rate variability and a positive signal 
averaged electrocardiogram, the relative risk for arrhythmic events 
was 18.5 times greater (p <0.0000).(10) 
Recently, microvolt T-wave alternans has been advocated as a 
methodology to reduce the number of ICD implants.(11) The 
Alternans Before Cardioverter Defibrillator (ABCD) trial indicated 
that a positive microvolt T-wave alternans test can predict who is at 
greatest risk. Other data dispute this finding.(12,13) Microvolt T-wave 
alternans testing has not been incorporated into current risk strati-
fication strategies. 
Electrophysiological testing has been used to predict risk. However, 
it is insensitive and non-specific, even for patients with coronary 
artery disease. The Multicentre Unsustained Tachycardia Trial 
(MUSTT) included patients with ischaemic heart disease, NSVT 
and LVEF ≤40%. The five-year SCD risk was 25% for those receiving 
156
electrophysiologically-guided therapy versus 32% for those assigned 
to no anti-arrhythmic therapy (p <0.001). Additionally, the five year 
mortality was 42% and 48% respectively (p =0.005).(14) While the 
differences were statistically significant, the clinical relevance of this 
difference is questionable. Electrophysiological testing is no longer 
considered a risk stratification strategy for determining the need 
for an ICD.(15)
There are many non-specific predictors of SCD including an 
elevated high sensitivity CRP; positive family history of sudden 
death; male sex; reduced water intake; abstaining from alcohol; 
times around holidays; and a lack of religious belief.(16-19) While 
men appear to be at high risk for SCD, dogs as pets appear to 
modulate this risk substantially.(20) One could even draw a geo-
graphic map of where the risk for SCD is greatest and then only 
target individuals who live in that area. This information highlights 
the absurdity of trying to define risk for sudden cardiac death using 
non-specific predictors.  
the goAl of IdeAl therApy Is to                       
prevent scd
The goal of an ideal therapy is to prevent SCD and  improve survival 
including maintaining quality-of-life and individual autonomy. An 
ideal therapy would also be highly effective, low risk and low cost. 
Several time-honoured and well-tested therapies can improve 
survival in patients with cardiovascular disease especially when 
cardiomyopathy is present. These include beta-adrenergic blocking 
drugs;(21) angiotensin converter inhibitors; aldosterone antagonists; 
and statins in selected patients.(22) These therapies and changing 
demographics have had a major impact. Today, the risk of SCD is 
much less than years past.(23,24) Other therapies, including diuretics, 
digitalis and nitrates used to treat cardiovascular conditions have 
not been shown to improve long-term survival in the general 
population.
Anti-arrhythmic drugs were once considered the mainstay of 
therapy to prevent SCD in patients at risk. Anti-arrhythmic drugs 
can suppress arrhythmias but they can also be pro-arrhythmic and 
therefore increase the risk of SCD.(25) Specific drugs that are 
potentially dangerous in patients with structural heart disease 
include the Class I drugs: procainamide; quinidine; mexiletine; 
propafenone; flecainide; encainide; and moricizine. Based on the 
Cardiac Arrhythmia Suppression Trial (CAST) I and II and many 
other trials,(25,26) these drugs can substantially increase the risk of 
SCD even though they may suppress ventricular arrhythmias. Class 
III drugs may be safer but no data support their use as life saving 
agents.(27-29) Amiodarone, whose stated indication is to treat life-
threatening ventricular arrhythmias, has not been shown to de-
crease the risk for SCD in patients at risk. Amiodarone has been 
extensively tested in various populations and has not been con-
vincingly associated with improved long-term outcome yet.(30-32)
Icds treAt vf, reduce scd, IMprove survIvAl  
And sAve lIves
ICDs have been shown in many well-controlled studies to improve 
outcomes including total mortality in patients at risk for SCD. 
Based on these studies, several guidelines have been written recom-
mending when an ICD should be considered.(33,34) The Anti-
arrhythmics Versus Implantable Defibrillators (AVID) trial and the 
Canadian Implantable Defibrillator Study (CIDS) are large multi-
centre trials focusing on the utility of ICDs for secondary preven-
tion.(35,36) In the AVID trial, the relative benefit included a 39% 
reduction in total mortality at one year. The absolute benefit 
included a 9% reduction in mortality at one year.(35) The cost per 
life year saved was $100 000.(37) There was additional survival of 
2.8 months (p <0.02). Despite the relative risk reduction compared 
with anti-arrhythmic drugs (particularly, amiodarone), the addi-
tional gain in life (measured in days) was rather inconsequential. 
This raises questions to the value of the therapy. The other major 
secondary prevention trial, the CIDS trial, was inconclusive.(36)  
Most importantly, there have been a large number of trials focusing 
on the utility of ICDs for primary prevention in patients with 
ischaemic cardiomyopathy and non-ischaemic cardiomyopathy. 
While many studies have shown the benefit of ICDs in select 
populations,(14,35,38-41) not all of these studies have demonstrated 
benefit.(42,43) Some of these studies demonstrate benefit but did 
not reach statistical significance.(44,45) Other studies are negative 
and have not shown the benefit in high risk populations.(43) 
 
The Multicentre Automatic Defibrillator Implantation Trial (MADIT II) 
compared defibrillator against “conventional” therapy in patients 
with ischaemic heart disease and poor ejection fraction (LVEF 
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≤30%).(41) The number requiring treatment, the cost per life year 
saved, and the reduction in total mortality, was much more in line 
with what was expected of a primary prevention trial. These data 
were supported by the Sudden Cardiac Death in Heart Failure 
Trial (SCD-HeFT), which included a diverse population of patients 
with ischaemic and non-ischaemic cardiomyopathy who were 
treated for congestive heart failure.(38) The SCD-HeFT population 
had LVEF ≤35% and NYHA functional Class II-III heart failure. 
Patients were randomised to placebo, amiodarone or ICD therapy 
and followed up over the long term. There was a 23% relative risk 
reduction in ICD therapy group (p =0.007) (Figure 1). However, 
the majority of heart failure patients with high risk are dying of 
end stage heart failure in the hospital instead of SCD.(7)  
Further analysis of this trial has demonstrated that patients with 
renal insufficiency, who cannot walk more than 900 feet on a six 
minute walk test, with atrial fibrillation or syncope(46) do not benefit 
as much from an ICD and may be at risk of death regardless. In 
addition, patients with NYHA functional Class III congestive heart 
failure did not seem to achieve benefit. These data highlight the 
fact that patients with multiple co-morbidities and those who are 
“sicker” may not benefit from an ICD. Recent analysis of the SCD-
HeFT data further highlights this. The study shows that a compo- 
site of co-morbid factors can identify subsets of heart failure 
patients in SCD-HeFT in whom an ICD therapy was of no benefit.(47) 
Data from the Inhibition of Unnecessary RV Pacing with AV 
Search Hysteresis in ICDs (INTRINSIC RV) study corroborate 
these findings.(48)  
MADIT-I (192)
1996
AVID (266)
1997
CABG-Patch (265)
1997
CASH* (643)
2000
CIDS (642)
2000
MADIT-II (268)
2002
DEFINITE (648)
2004
DINAMIT (152)
2004
SCD-HeFT (7a)
2005
fIgure 1: major clinical trials of device therapy for primary and secondary prevention of sudden cardiac death (Zipes dp, camm AJ, borggrefe m, 
et al. Acc/AHA/Esc 2006 Guidelines for management of patients with ventricular Arrhythmias and the prevention of sudden cardiac death: 
A report of the American college of cardiology/American Heart Association task force and the European society of cardiology committee for 
practice Guidelines (Writing committee to develop Guidelines for management of patients With ventricular Arrhythmias and the prevention of 
sudden cardiac death). J Am coll cardiol. sep 5 2006;48(5):e247-346.)
MADIT-1: Multicentre Automatic Defibrillator Implantation Trial I, AVID: Anti-arrhythmics Versus Implantable Defibrillators, CABG-Patch: Coronary Artery Bypass Graft (CABG) Patch Trial, 
CASH: Cardiac Arrest Study Hamburg, CIDS: Canadian Implantable Defibrillator Study, MADIT-II: Multicentre Automatic Defibrillator Implantation Trial II, DEFINITE: The Defibrillators in Non- 
ischaemic Cardiomyopathy Treatment Evaluation, DINAMIT: Defibrillator in Acute Myocardial Infarction Trial, SCD-HeFT: Sudden Cardiac Death in Heart Failure Trial, LVEF: Left ventricular 
ejection fraction, NSVT: Non-sustained ventricular tachycardia, EP: Electrophysiology, SAECG: Signal Averaged Electrocardiogram, MI: Myocardial infarction, PVC: Premature ventricular complex, 
NICM: Non-ischaemic cardiomyopathy, LVD: Left ventricular dysfunction.
ICD better
0.4
0.35 or less, NSVT, EP positive
Aborted cardiac arrest
0.35 or less, abnormal SAECG and scheduled 
for CABG
Aborted cardiac arrest
Aborted cardiac arrest or syncope
0.30 or less, prior MI
0.35 or less, NICM and PVCs or NSVT
0.35 or less, MI within 6 to 40 days and 
impaired cardiac autonomic function
0.35 or less, LVD due to prior MI and NICM
Hazard ratio
0.6 0.8 1.0 1.2 1.4 1.6 1.8
N = 196
0.46
N = 1 016
0.62
N = 900
1.07
N = 191
0.83
N = 659
0.82
N = 1 232
0.69
N = 458
0.65
N = 674
1.08
N = 1 676
0.77
Trial Name
Pub Year
LVEF, other features
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concerns About Icds                                            
As more data become available through registries and randomised 
controlled clinical trials, concerns have arisen, including differences 
in implantation rates based on race and gender ; recalls of both 
ICDs and leads; and inappropriate shocks for sinus tachycardia, 
NSVT or atrial fibrillation. A procedure complication is an im-
portant issue, especially when it comes to revising systems or 
placing new pulse generators. There are restrictions for patients 
who receive ICDs. In the United States, for example, individuals 
with ICDs cannot drive commercially.  
race and gender versus Icd implantation
Data regarding race and gender equipoise remains a concern. In 
a recent report looking at the “Get with the guidelines” pro- 
gramme for the American Heart Association, of those eligible for 
an ICD less than 40% actually received one.(51) Compared with 
white men, black men were less likely and white women were 
even less likely to receive ICDs when exhibiting the required 
indications. The group least likely to receive an ICD despite required 
indications was black women with 44% less chance compared with 
white men.
Based on a study that compared ICD recipients in Medicare 
Database to a heart failure cohort without ICDs,(52) there was no 
clear-cut benefit in an ICD implant for primary prevention. While 
these populations may not be entirely comparable, it raises issues 
about the need for ICDs in this population. For secondary 
prevention, there appeared to be a benefit of receiving an ICD. 
Women were less likely than men to receive ICDs both for pri-
mary and secondary prevention. 
Recent data indicate that women are at greater risk for complica-
tions and benefit less from ICDs.(53) Women who receive ICDs 
tend to be older with more co-morbidities. They are more likely to 
die of non-arrhythmic causes than men. In-hospital complications 
for ICDs were substantially greater for women than men  both in 
implants for primary and secondary prevention. This was true for 
all complications and major adverse events. This information has 
been substantiated in the INTRINSIC RV trial.(54)
policing effect of Icd in the Us population
In the US patients need to complete a National Cardiovascular 
Data Registry (NCDR) form to receive an ICD. The plan is to 
the experts dIsAgree on  A current               
recoMMendAtIon
Approximately 14 years ago, Stevenson and Ridker published an 
article in JAMA(49) stating that ICDs may benefit 1 in 14 if the LVEF 
is ≤40% after myocardial infarction.  While the number needed to 
treat to save one life appears to be in line with what we would 
expect, these investigators felt that the risk of SCD is so low 
that “routine referral to an arrhythmia specialist is not warranted”. 
Actually, the number needed to treat for one life saved is one of 
the best deals we have in cardiology.
In the United States, the Combined Medicare Medicaid Services 
have developed a “decision summary” in which they include the 
criteria for ICD implantation.(50) For primary prevention, they 
include patients with ischaemic or non-ischaemic cardiomyopathy 
with NYHA II-III heart failure and LVEF ≤35%; no myocardial 
infarction within 40 days; no bypass surgery or revascularisation 
within three months; and no acute diagnosis of dilated cardio-
myopathy within three months. Furthermore, ICDs are considered 
“reasonable and necessary” if there is ischaemic or non-ischaemic 
cardiomyopathy and LVEF ≤30% without heart failure symptoms 
on proper medical management. For secondary prevention, patients 
who have had prior VT or VF that is otherwise unexplained are 
ICD candidates. Other potential conditions include hypertrophic 
cardiomyopathy; right ventricular cardiomyopathy; long QT interval 
syndrome; catecholamine-induced polymorphic ventricular tachy-
cardia; and idiopathic ventricular fibrillation among others (Table 1). 
Unfortunately, the definition of high risk remains uncertain for 
many of these diseases and the best way to determine who should 
receive an ICD remains a matter of discussion.(33)
Another concern is for people with borderline risk, for example, 
patients with diastolic heart failure or with only mild ventricular 
dysfunction. These patients remain at high risk but may not be as 
high as patients with severely impaired ventricular function. We 
have not yet defined which patient with valvular heart disease 
should have ICDs. There are little data concerning patients with 
mild QT prolongation or mild left ventricular hypertrophy. Further-
more, limited data is available regarding patients with mild ventri-
cular dysfunction and syncope or patients with a positive family 
history of sudden death.  
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tAble 1:  Indications for Implantable cardioverter defibrillator 
(Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and 
Anti-arrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. May 27 2008;51(21):e1-62.
class I: Icd therapy is indicated in patients: 
 Who are survivors of cardiac arrest due to ventricular fibrillation or haemodynamically unstable sustained VT after evaluation to define the cause of the event and to exclude 
any completely reversible causes;
With structural heart disease and spontaneous sustained VT, whether haemodynamically stable or unstable;
With syncope of undetermined origin with clinically relevant, haemodynamically significant sustained VT or ventricular fibrillation induced at electrophysiological study;
With LVEF less than 35% due to prior myocardial infarction who are at least 40 days post-myocardial infarction and are in NYHA functional Class II or III;
With non-ischaemic dilated cardiomyopathy who have an LVEF less than or equal 35% and who are in NYHA functional Class II or III;
 With LV dysfunction due to prior myocardial infarction and are at least 40 days post-myocardial infarction, have an LVEF less than 30%, and are in NYHA functional  
Class I; and
With non-sustained VT due to prior myocardial infarction, LVEF less than 40%, and inducible ventricular fibrillation or sustained VT at electrophysiological study.
class IIa: Icd implantation is reasonable: 
For patients with unexplained syncope, significant LV dysfunction, and non-ischaemic dilated cardiomyopathy;
For patients with sustained VT and normal or near-normal ventricular function;
For patients with hypertrophic cardiomyopathy who have 1 or more major risk factor for SCD;
For the prevention of SCD in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy who have 1 or more risk factor for SCD;.
To reduced SCD in patients with long-QT syndrome who are experiencing syncope and/or VT while receiving beta blockers;
For non-hospitalised patients awaiting transplantation;
For patients with Brugada syndrome who have had syncope;
For patients with Brugada syndrome who have documented VT that has not resulted in cardiac arrest;
For patients with catecholaminergic polymorphic VT who have syncope and/or documented sustained VT while receiving beta blockers; and
For patients with cardiac sarcoidosis, giant cell myocarditis, or Chagas disease.
class IIb: Icd therapy may be considered: 
In patients with non-ischaemic heart disease who have an LVEF of less than or equal to 35% and who are in NYHA functional Class I;
For patients with long-QT syndrome and risk factors for SCD;
In patients with syncope and advanced structural heart disease in whom thorough invasive and non-invasive investigations have failed to define a cause;
In patients with a familiar cardiomyopathy associated with sudden death; and
In patients with LV non-compaction.
class III: Icd therapy is not indicated for: 
 Patients who do not have a reasonable expectation of survival with an acceptable functional status for at least 1 year, even if they meet ICD implantation criteria specified in the 
Class I, IIa, and IIb recommendations above;
Patients with incessant VT or ventricular fibrillation;
Patients with significant psychiatric illness that may be aggravated by device implantation or that may preclude systematic follow-up;
 NYHA Class IV patients with drug-refractory congestive heart failure who are not candidates for cardiac transplantation or implantation of a CRT device that incorporates both 
pacing and defibrillation capabilities;
For syncope of undetermined cause in a patient without inducible ventricular tachyarrhythmia and without structural heart disease;
 When ventricular fibrillation or VT is amenable to surgical or catheter ablation (e.g. atrial arrhythmias associated with Wolff-Parkinson-White syndrome; right ventricular or LV 
outflow tract; idiopathic VT; or fascicular VT in the absence of structural heart disease); and
Patients with ventricular tachyarrhythmias due to completely reversible disorder in the absence of structural heart disease (e.g. electrolyte imbalance, drugs, or trauma).
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
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continue the registry despite hundreds of thousands applicants 
having been registered. The form is complex and a deterrent for 
implanting an ICD. Nevertheless, several important pieces of 
information have resulted from the registry.(55)  Electrophysiologists 
were found to be the most common implanting physicians.  Elec-
trophysiologists did a better job at implanting ICDs than non-elec-
trophysiologists. Non-electrophysiology cardiologists and thoracic 
surgeons had substantially higher complication rates than the elec-
trophysiologists. This was true for both single and dual chamber 
ICDs and cardiac resynchronisation therapy devices.
Icd advisories and risks in perspective
Over the past several years, there have been many reports of ICD 
problems and risks.  These risks have been taken out of propor- 
tion to what they actually represent. For example, the Guidant 
Ventak Prizm AVT had an advisory date of June 2005 and the 
current risk of failure was 0.0095%.(56,57) Removing all these ICDs 
would increase the risk of mortality and adverse effects by many 
orders of magnitude. There have also been advisories developed 
by both St. Jude and Medtronic. Of greater concern is the Fidelis 
Medtronic lead. The failure rate in long-term follow-up is 5% and 
may be as great as 10%.(58) However, the risk of extraction of these 
leads may be at least this high. It is uncertain if placing a new lead 
will lower the risk due to the  risk of infection and other complica-
tions. On the other hand, if this lead fails with disruption in the 
installation, patients can receive inappropriate shocks and die as a 
result. Remote monitoring may help decrease this risk.
Several registries have been developed, helping to better define 
the risks of maintaining leads and placing new leads and devices. 
The risk of complications from ICDs in general practice may far 
exceed that seen in controlled clinical trials. Therefore the actual 
benefit of an ICD in clinical practice may not be anywhere near 
what is seen in controlled clinical trials.
types of Icds: How to select
Three kinds of ICDs exist: 
Single-chamber ICDs;
Dual-chamber ICDs; and 
Cardiac Resynchronisation Therapy ICDs. 
 
It remains uncertain who should get a dual chamber ICD versus a 
single chamber ICD.  Most of the controlled clinical data showing 
■
■
■
benefits have looked at single chamber ICDs and ICDs that reduce 
right ventricular pacing. New pacing algorithms can minimise the 
risk of right ventricular pacing in dual chamber ICDs. Dual chamber 
ICDs have potential benefits as they can pace the atria (and 
ventricles) as necessary and help identify the specific arrhythmia 
that led to the shock. While not all the data have shown that dual 
chamber devices can better discriminate the need for therapy, 
they can help post hoc determine what the arrhythmia was and 
what therapy maybe best in the future. There is no consensus 
about which type of an ICD (single or dual chamber) is the best to 
implant for most patients.(59,60) Based on NCDR data (only acces-
sible by members), implanting physicians in the United States use 
dual chamber devices far more frequently than single chamber 
devices.
Resynchronisation therapy ICDs are for selected high risk patients 
with low LVEFs and wide QRS complexes, especially those with left 
bundle branch block. Cardiac resynchronisation devices can reduce 
the risk of SCD and substantially improve functional class in patients 
with significant congestive heart failure(61) with pacing alone even if 
no defibrillation back-up is present.(62) 
Appropriate and inappropriate shocks
It is still unclear if ICD shocks, especially inappropriate shocks, can 
affect outcomes adversely. Data from the SCD-HeFT trial would 
suggest that receiving a shock versus no shock is associated with a 
hazard ratio of 11.27 (p <0.001) for death. The hazard ratio of 
an appropriate versus no appropriate shocks is 5.68 (p <0.001). 
The hazard ratio of inappropriate shocks versus no inappropriate 
shocks is 1.98 (p =0.002).(63)  The actual meaning of these remains 
uncertain since inappropriate shocks are often due to atrial fibril-
lation which in itself is associated with increased risk of death. 
Similar data were found in the MADIT II population.(64) 
While there are those who state that any shock can affect out-
comes adversely, this contention is nonsensical when an ICD shock 
is for a life-threatening arrhythmia: without it the patient would be 
dead. Furthermore, all data suggesting adverse effects of shocks is 
flawed by the fact that those patients who received a shock are 
clearly different than those who do not receive shocks: one group 
has an arrhythmia and the other group does not. Alternatively, 
perhaps fewer shocks are needed and anti-tachycardia pacing may 
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help reduce the need for shocks when a sustained ventricular 
tachyarrhythmia occurs.
The Prepare Parameters Evaluation Trial (PREPARE) has demon-
strated that strategic programming of tachycardia detection and 
therapy parameters can reduce ICD shocks. This uniform pro-
gramming approach is better than the individually guided pro-
grammed setting to detect tachyarrhythmias.(65) 
A new study, the Multicentre Automatic Defibrillator Implantation 
Trial-Reduced Inappropriate Therapy (MADIT-RIT) trial is under-
way. This study is comparing three programming schema (standard 
rate, high rate and prolonged detection) to see which will reduce 
unneeded shocks without incurring excess risk. Fifteen hundred 
patients are planned for this study and the study is now enrolling. 
The outcome is the time to first inappropriate therapy. Other 
endpoints include total mortality.
Are there too MAny Icd IMplAnts?                     
The question about the need for ICD implantation raises several 
important medical and philosophical issues. Many patients who 
receive ICDs ultimately will be at risk for death from other causes 
and not benefit from an ICD. This is clear from the SCD-HeFT 
data.(7)  Patients with long QT syndrome and Brugada syndrome 
may have risk of SCD as low as 0.5 % per year, yet implants continue 
for those patients.(66,67) Further, there are no randomised studies in 
many populations for whom devices are routinely placed.  
ICDs can also complicate some end-of-life decisions. There is no 
consensus about when to turn off a device. The actual promise of 
ICDs and what should be expected in the long-term should be 
discussed upfront with patients. Furthermore, there is a so-called 
“Dick Cheney effect”. Dick Cheney, the former US vice president, 
received an ICD as he was considered at risk for SCD even though 
he did not meet the strict criteria. Like Dick Cheney, many patients 
fit into the “grey zone” where they have mild impairment of ven-
tricular function but do not reach LVEF ≤35%.   
As the public considers the need for ICDs and evaluates the utility 
for ICDs, it becomes even more questionable at what level the 
ICD would be appropriate. For example, Consumer Reports, an 
American publication that evaluates various consumer products 
for the public need and benefit, have considered the ICD to be 
one of “10 overused medical tests and treatments”. In an article 
about “how US healthcare bill got to record-breaking $2 trillion”, 
they state “… how consumers can navigate a healthcare system 
that rewards costly and often unnecessary tests and procedures 
and de-emphasises preventive care”. On ICDs they state that 
“one third might not need them, research shows”.(68) This shows 
how the public considers a therapy. In fact, if one in 14 used the ICD 
as a life saving device, it would likely be worth implanting these 
devices. 
This public media view has also been highlighted in the New York 
Times which stated that “nine of 10 people who get ICDs received 
no medical benefit”.(69) This is probably correct but it is a jilted view 
of a valid medical therapy. In fact, they stated that “ICDs have 
saved the lives of 10% of the greater than 600 000 people in this 
country who received them”. This means a large number of people 
have benefited from ICDs. They also stated “people must weigh the 
risks of infection and malfunction after they have an electronic 
device anchored inside their hearts and its wires threaded through 
their arteries”. Clearly, the general population does not understand 
exactly what an ICD is, what it does and who it benefits. It highlights 
the idea that the general population and even the federal govern-
ment probably should not be put in a position of judging how to 
use medical therapies and devices.
Are there too feW Icds IMplAnted?                    
Data from the United States shows that only about 35% of those 
who meet ICD criteria actually get the device. A study from the 
Netherlands also highlights this issue. In terms of primary preven-
tion, only 7% of those patients with LVEF ≤30% actually received 
an ICD.(70) Patients at risk for SCD who did not meet this criterion 
did not receive an ICD.  With respect to those patients who had 
spontaneous poorly tolerated VT, only 10% received ICDs. In fact, 
of the 135 patients with ICD indication, only 19 received an ICD. 
Of those 1 751 patients who did not have an ICD indication, none 
of them received an ICD.
Several opinions have been published including a recent state-of-
the-art paper by Tung et al. stating that “potential hazards of ICD 
therapy will enable physicians to have a more mutually informed 
and balanced dialogue with their patients”.(71) This has been com-
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mented on by Epstein stating that the risks of ICD therapy are 
potentially over-emphasised in lieu of the substantial benefits.(72) 
 
SCD remains a major killer. Most victims are not even identified 
before death. For many individuals at risk, we have no data to know 
whether or not they should have an ICD implant. Furthermore, 
many individuals, if not most, are at borderline risk for SCD.
Icds In south AfrIcA                                                       
ICD implant rates in South Africa are not as high as they are in 
several other countries including the United States. Government 
reimbursement appears to be low. Those with private insurance 
may have a much greater chance of receiving an ICD. The poten- 
tial benefit of ICDs in reducing the risk of SCD and lowering total 
mortality is not necessarily the same in South Africa as it is in the 
United States. Underlying cardiac diseases may be different be-
tween countries and risks of SCD even for the same condition may 
vary by country. In South Africa, there is a greater incidence of 
valvular heart disease and idiopathic cardiomyopathy than in the 
United States. There are also more deaths from non-cardiovascular 
causes including communicable disease so that SCD in the South 
African population may pale in comparison to other causes of 
death and disease.
conclusIon                                                                 
ICDs represent a step forward in the treatment of patients with 
cardiovascular disease when there is a risk for SCD. ICDs can 
improve total mortality in those patients who have high risk of 
SCD due to VT or VF. There are continuing challenges that must 
be considered including identifying when ICDs provide real bene- 
fit in the light of risk and cost.
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